Zota Health Care Q2 FY25 revenue up 48.6%

Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%

Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, Q2 FY25 revenue was Rs. 67.28 crore an increase of 48.6% vis-a-vis FY24.

Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%.

Commenting on the Q2 FY25 performance, Ketankumar Zota, Chairman, Zota Health Care Limited said, “We are pleased to announce a robust performance this quarter, marked by 49% revenue growth driven by rising demand for our products. As a part of our expansion strategy, we launched 133 new Davaindia stores in Q2 FY25, including 114 COCO stores to build a strong, self-operated network, along with 19 FOFO stores. This expansion brings our total store count to 1,165, reinforcing our nationwide presence and commitment to accessible healthcare. Our expanding reach is attracting increasing foot traffic, with footfalls rising from Rs. 12.22 lakh in Q2 FY24 to ₹22.23 lakh in Q2 FY25, underscoring the rising demand for affordable pharmaceuticals in India." 

"Gross Merchandise Value (GMV) also surged from Rs. 31.59 crore in Q2 FY24 to Rs. 55.54 crore this quarter. Our efforts to enhance the consumer experience are reflected in an increased average wallet spend per visit, now at Rs. 233 and Rs. 282 in COCO and FOFO in H1FY25 respectively. As we move forward, we remain dedicated to meeting the diverse healthcare needs of India's population and reinforcing our position at the forefront of the generic retail pharmacy sector,” added Zota.